Barclays Maintains a Buy Rating on Sarepta Therapeutics (SRPT)

By Carrie Williams

Barclays analyst Gena Wang maintained a Buy rating on Sarepta Therapeutics (SRPTResearch Report) on December 13 and set a price target of $202.00. The company’s shares closed last Monday at $132.05.

According to TipRanks.com, Wang is a 5-star analyst with an average return of 19.7% and a 50.9% success rate. Wang covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Puma Biotechnology, and Eidos Therapeutics.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Sarepta Therapeutics with a $204.06 average price target, which is a 62.6% upside from current levels. In a report issued on December 13, Cantor Fitzgerald also maintained a Buy rating on the stock with a $211.00 price target.

See today’s analyst top recommended stocks >>

Based on Sarepta Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly GAAP net loss of $126 million. In comparison, last year the company had a GAAP net loss of $76.39 million.

Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of SRPT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.